Has points of clarification what I said about an immune response...

Has points of clarification what I said about an immune response was in relation to why patients in the first two cohorts cannot be re-treated. With regard to what efficacy could be inferred from results from the first two cohorts what I said was these results could be compared to those from NHP at similar dosing regimes. From this comparison it may be possible to extrapolate expected results for higher doses.

I would now add that the first dosing level in humans has NO corresponding dosing levels in NHP. It is below the lowest NHP dose. As such we may have to wait until the second cohort results are known before any extrapolation can occur as this dosing level corresponds to the lowest level of NHP dosing.

The third cohort has no corresponding NHP dosing level. The fourth cohort corresponds to the mid NHP dosing level and the fifth cohort dose is at a level in between the mid and highest NHP levels.